Alterity Therapeutics (NASDAQ:ATHE) Director Purchases $23,810.00 in Stock

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Director Peter Ashley Marks purchased 47,620 shares of the stock in a transaction dated Monday, August 31st. The stock was acquired at an average cost of $0.50 per share, for a total transaction of $23,810.00. Following the transaction, the director owned 191,340 shares of the company’s stock, valued at approximately $95,670. This trade represents a 33.13% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Alterity Therapeutics Stock Down 8.7%

ATHE opened at $4.11 on Friday. The company has a 50 day moving average of $4.74 and a 200 day moving average of $4.32. Alterity Therapeutics Limited – Sponsored ADR has a 12 month low of $2.66 and a 12 month high of $5.89.

Alterity Therapeutics (NASDAQ:ATHE) last issued its earnings results on Thursday, July 30th. The company reported ($0.28) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million for the quarter. As a group, equities analysts forecast that Alterity Therapeutics Limited – Sponsored ADR will post -0.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alterity Therapeutics

An institutional investor recently raised its stake in Alterity Therapeutics stock. Greenleaf Trust boosted its holdings in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) by 93.8% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,000 shares of the company’s stock after acquiring an additional 30,000 shares during the quarter. Greenleaf Trust owned 0.70% of Alterity Therapeutics worth $333,000 at the end of the most recent reporting period. Institutional investors own 2.14% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on ATHE shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. LADENBURG THALM/SH SH began coverage on Alterity Therapeutics in a research note on Tuesday, June 16th. They issued a “buy” rating and a $10.00 target price for the company. Craig Hallum set a $2.00 target price on Alterity Therapeutics in a report on Tuesday, August 11th. Zacks Research upgraded Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Finally, JonesTrading started coverage on Alterity Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $16.00 price target on the stock. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $10.00.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.